RCC2 and cancer: However, there was no significant difference in the 5-year RFS rate according to RCC2 expression in the QUASAR2 cohort (HR 1.13, 95% CI 0.90 to 1.42, log-rank p=0.28, N=1090, figure 2B), irrespective of cancer stage (stage II or III, online supplemental figure 5) or treatment regimen (online supplemental figure 6).